Nanocytology Test to Evaluate Skin Cancer in High Risk Patients
Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients
Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients
Sponsor study identifier
interventional
7
1 country
1
Study Start
July 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2014
Actual (reported)Study Completion
November 2014
Actual (reported)The purpose of this study is to correlate pathological features from specimens in order to determine if this new molecular diagnostic technique can be used to detect risk of skin cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2014
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 2013
Date type not reportedThis date has not been verified as actual or estimated.
July 18, 2013
Actual (reported)July 23, 2013
Actual (reported)November 2014
Actual (reported)November 2014
Actual (reported)Nanocytology assessment of skin cancer risk
The primary outcome measure is to correlate clinical phenotype (age, skin phototype, level of photodamage, history of prior skin cancers) with morphology and nuclear characteristics, in order to determine if this new molecular diagnostic technique can be used to detect early stages of skin carcinogenesis and identify high risk-patients.
1 year
Compare nanocytology assessment with pathological findings
1 year
Subjects at risk of skin cancer (sun-damaged skin) a superficial shave biopsy will be performed.
Subjects without sun-damaged skin a superficial shave biopsy will be performed.
Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
Joan Guitart, MD
Northwestern University
7 participants (actual enrollment reported by the registry).
First Submitted
July 18, 2013
First Posted
July 23, 2013
Study Start
July 2013
Date type not reportedThis date has not been verified as actual or estimated.
Development and Validation of a Quality of Life Instrument for Actinic Keratosis
Contact the study team to confirm eligibility.
Primary Completion
November 2014
Actual (reported)Study Completion
November 2014
Actual (reported)Last Updated
November 19, 2014
Record last verified: 2014-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: